Immunovant, Inc.
IMVT
Ранг среди акций
#3062
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Цена акции
$28.32
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$5.85B
Изменение (1 день)
-0.94%
Изменение (1 год)
49.85%
Страна
US
Торговля Immunovant, Inc. (IMVT)
Категория
Healthcare
История цены акций Immunovant, Inc. (IMVT)
Наивысшая цена закрытия: $30.02 2026-10-01
Наименьшая цена закрытия: $9.88 2019-06-01
Наименьшая цена закрытия: $9.88 2019-06-01
История цены акций Immunovant, Inc. с 2019 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | 20.78% |
| 2025 | -7.38% |
| 2024 | -34.45% |
| 2023 | 163.89% |
| 2022 | 99.44% |
| 2021 | -84.02% |
| 2020 | 273.47% |
| 2019 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.24 | 7.63% |
CH
|
